Disorders of Movement

Disorders of Movement

This chapter describes three types of movement disorder: (a) involuntary movements (i.e., seizures), (b) weak or ineffective movements (i.e., neuromuscular weakness), and (c) no movements (i.e., drug-induced paralysis).

I. Seizures

A. Types of Seizures

Seizures are classified by the extent of brain involvement (generalized vs. focal seizures), the presence or absence of abnormal movements (convulsive vs. nonconvulsive seizures), and the type of movement abnormality (e.g., tonic, clonic, etc.).

1. Abnormal Movements

The movements caused by seizures can be tonic (sustained muscle contraction), clonic (rhythmic movements with a regular amplitude and frequency), or myoclonic (irregular, twitchy movements) (1). Some movements are familiar (e.g., chewing) and repetitive; these are called automatisms.

2. Generalized Seizures

Generalized seizures arise from synchronous, rhythmic electrical discharges that involve most of the cerebral cortex, and they are always associated with loss of consciousness.
These seizures typically produce tonic-clonic movements of the extremities, but they can also occur without abnormal movements (generalized nonconvulsive seizures) (2).

3. Partial Seizures

Partial seizures can arise from diffuse or localized rhythmic discharges, and the clinical manifestations can vary widely, as demonstrated by the following two examples.

  • Partial complex seizures are nonconvulsive seizures that produce behavioral changes, and can be accompanied by repetitive chewing motions or lip smacking (automatisms). These seizures are a common cause of nonconvulsive status epilepticus, but they do not appear de novo in critically ill patients (2).

  • Epilepsia partialis continua is a convulsive seizure that is characterized by persistent tonic-clonic movements of the facial and limb muscles on one side of the body.

4. Myoclonus

Myoclonus (irregular, jerking movements of the extremities) can occur spontaneously, or in response to painful stimuli or loud noises (startle myoclonus). These movements can be seen in any type of encephalopathy (metabolic, ischemic). Myoclonus is not universally regarded as a seizure because it is not associated with rhythmic discharges on the EEG (3).

B. Status Epilepticus

Status epilepticus can be defined as 5 minutes of continuous seizure activity, or two seizures without an intervening period of consciousness (4). This can involve any type of seizure, and can be “convulsive” (i.e., associated with abnormal movements) or “nonconvulsive” (i.e., not associated with abnormal movements).

1. Nonconvulsive Status Epilepticus

Most cases of nonconvulsive status epilepticus (NSE) involve partial complex seizures (which are not common in ICU patients), but as many as 25% of generalized seizures can be nonconvulsive (5).

  • Generalized NSE is accompanied by loss of consciousness, and can be an occult source of coma in ICU patients (see Chapter 40, Section IV-D).

C. Predisposing Conditions

A variety of conditions can promote new-onset seizures in critically ill patients. In one survey, the most common predisposing conditions were drug intoxication, drug withdrawal, and hypoglycemia (6). Other predisposing conditions include metabolic encephalopathies (e.g., liver failure, uremia), ischemic and traumatic brain injuries, intracranial mass lesions, and meningoencephalitis.

D. Acute Management

The following recommendations (unless otherwise cited) are from the most recent guidelines on convulsive status epilepticus (CSE) from the American Epilepsy Society (7).

1. Fingerstick Blood Glucose

The initial encounter should include a fingerstick blood glucose level. If the blood glucose is <60 mg/dL, administer IV boluses of D50 (50 mL) and thiamine (100 mg).

2. Stage 1 Drugs

The most effective drugs for rapid termination of CSE are the benzodiazepines, which are effective in 60–80% of cases.

  • LORAZEPAM: Intravenous lorazepam (4 mg IV over 2 minutes) is the drug of choice for terminating CSE.
    The onset of action is <2 minutes, and the full dose can be repeated after 5–10 minutes, if necessary.

  • MIDAZOLAM: The benefit of midazolam is rapid up-take when given by intramuscular (IM) injection. When IV access is not available, midazolam can be given IM in a dose of 10 mg. The efficacy in terminating CSE is equivalent to IV lorazepam, and the onset of action is only slightly longer than with IV lorazepam (e.g., one study showed a median onset of 3.3 minutes with IM midazolam vs. 1.6 minutes with IV lorazepam) (8).

3. Stage 2 Drugs

Stage 2 drugs are used for seizures that are refractory to benzodiazepines, or are likely to recur within 24 hours. These drugs include phenytoin, fosphenytoin, valproic acid, and levetiracetam.

  • PHENYTOIN: The IV dose of phenytoin is 20 mg/kg, or a maximum dose of 1,500 mg. Phenytoin cannot be infused faster than 50 mg/min because of the risk of cardiac depression and hypotension.

  • FOSPHENYTOIN: Fosphenytoin is a water-soluble phenytoin analogue that produces less cardiac depression, and can be infused three times faster than phenytoin (150 mg/min) (12). It is as effective as phenytoin, and is preferred because of the reduced risk of hypotension (7).

  • VALPROIC ACID: The IV dose of valproic acid is 40 mg/kg, or a maximum IV dose of 3,000 mg. Although considered equivalent to phenytoin in efficacy (7), a recent meta-analysis showed that valproic acid is superior to phenytoin for terminating benzo-diazepine-resistant CSE (9).

    Table 41.1 Drug Regimens for Status Epilepticus

    Drug Dosing Regimens and Comments
    Stage 1 Drugs
    Lorazepam Dosing: 4 mg IV over 2 min. Repeat in 5–10 min, if necessary.
    Comment: Initial treatment of choice. Onset of action typically <2 min.
    Midazolam Dosing: 10 mg by intramuscular (IM) injection.
    Comment: As effective as IV lorazepam, and preferred when IV access is not available.
    Stage 2 Drugs
    Phenytoin Dosing: 20 mg/kg IV or maximum single IV dose of 1,500 mg.
    Comment: Promotes cardiac depression and hypotension.
    Fosphenytoin Dosing: Same dose as phenytoin.
    Comment: Equal in efficacy to phenytoin, but has a more favorable safety profile.
    Valproic Acid Dosing: 40 mg/kg IV, or maximum single IV dose of 3,000 mg.
    Comment: Considered equivalent to phenytoin in efficacy.
    Levetiracetam Dosing: 60 mg/kg IV, or maximum single IV dose of 4,500 mg.
    Comment: Considered equivalent to phenytoin in efficacy.
    From Reference 7.

  • LEVETIRACETAM: The newest anticonvulsant for CSE is levetiracetam which is given in a single dose of 60
    mg/kg IV, or a maximum IV dose of 4,500 mg. This drug is also considered equivalent to phenytoin in efficacy (7), but a recent meta-analysis shows that it is superior to phenytoin for terminating benzodiazepine-resistant CSE (9).

4. Refractory Status Epilepticus

Ten percent of patients with CSE are refractory to stage 1 and 2 drugs (5). The recommended treatment at this point is anesthetic doses of one of the drugs in Table 41.2. Guidance from a neurologist (along with continuous electroencephalographic monitoring) is the best option at this stage.

Table 41.2 Drug Regimens for Refractory Status Epilepticus

Drug Dosing Regimens
Pentobarbital Load with 5–15 mg/kg IV over one hr, then infuse at 0.5–1 mg/kg/hr. If necessary, increase infusion rate up to 3 mg/kg/hr (maximum rate).
Thiopental Start with an IV bolus of 3–5 mg/kg, and follow with 1–2 mg/kg every 2–3 min until seizures subside. Then infuse 3–7 mg/kg/hr for the next 24 hrs.
Midazolam Load with 0.2 mg/kg IV, then infuse at 4–10 mg/kg/hr.
Propofol Start with IV bolus of 2–3 mg/kg, and use further boluses of 1–2 mg/kg, if needed, until seizure activity subsides. Then infuse at 4–10 mg/kg/hr for 24 hrs.
Dosing regimens from Reference 3.

Only gold members can continue reading. Log In or Register to continue

Nov 8, 2018 | Posted by in CRITICAL CARE | Comments Off on Disorders of Movement
Premium Wordpress Themes by UFO Themes